TEVA-COTRIDIN EXPECTORANT 100 MG / 5 ML
GUAIFENESIN : 100 MG / 5 ML TRIPROLIDINE HYDROCHLORIDE : 2 MG / 5 ML PSEUDOEPHEDRINE HYDROCHLORIDE : 30 MG / 5 ML CODEINE PHOSPHATE : 10 MG / 5 ML · DIN 02053403 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-COTRIDIN EXPECTORANT?
TEVA-COTRIDIN EXPECTORANT 100 MG / 5 ML contains GUAIFENESIN : 100 MG / 5 ML TRIPROLIDINE HYDROCHLORIDE : 2 MG / 5 ML PSEUDOEPHEDRINE HYDROCHLORIDE : 30 MG / 5 ML CODEINE PHOSPHATE : 10 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02053403, held by TEVA CANADA LIMITED, supplied as SYRUP for ORAL administration. Health Canada currently lists it as marketed, status dated 05-Mar-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-COTRIDIN EXPECTORANT used for?
Temporary relief of coughs associated with allergy or the common cold in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02053403 |
|---|---|
| Brand name | TEVA-COTRIDIN EXPECTORANT |
| Generic / active ingredient | GUAIFENESIN : 100 MG / 5 ML TRIPROLIDINE HYDROCHLORIDE : 2 MG / 5 ML PSEUDOEPHEDRINE HYDROCHLORIDE : 30 MG / 5 ML CODEINE PHOSPHATE : 10 MG / 5 ML |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 100 MG / 5 ML |
| Dosage form | SYRUP |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | R05FA02 OPIUM DERIVATIVES AND EXPECTORANTS |
| AHFS class | 48:08.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 05-Mar-2018 |
| Original market date | 1994-12-31 00:00:00 |
How is it administered?
Adults: 5 mL to 10 mL every 4 to 6 hours as required. Do not exceed 40 mL in 24 hours. Use the lowest effective dose for the shortest duration.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (refers to STORAGE AND STABILITY section).
How is it supplied?
Not explicitly detailed in the provided text (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section).
Contraindications
Patients <18 years; pregnant/breastfeeding women; CYP2D6 ultra-rapid metabolizers; MAOIs use; asthma; respiratory depression; hypertension; coronary artery disease; severe renal/hepatic impairment.
Warnings and precautions
Risk of addiction, abuse, misuse, and fatal respiratory depression. Concomitant use with benzodiazepines or alcohol may result in death. Risk of opioid toxicity in ultra-rapid metabolizers.
What can be used instead?
Other Canadian products sharing ATC code R05FA02 OPIUM DERIVATIVES AND EXPECTORANTS. 25 of 156 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BENYLIN EXTRA STRENGTH COUGH & CHEST CONGESTION | 200 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02265419 |
| BENYLIN EXTRA STRENGTH COUGH & CHEST CONGESTION WITH WARMING SENSATION | 15 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02003317 |
| BENYLIN EXTRA STRENGTH COUGH COMPLETE | 200 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02265400 |
| BENYLIN EXTRA STRENGTH FOR PEOPLE WITH DIABETES | 15 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02436485 |
| BENYLIN EXTRA STRENGTH MUCUS & PHLEGM PLUS COUGH CONTROL | 15 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02320959 |
| BENYLIN REGULAR STRENGTH COUGH PLUS CHEST CONGESTION RELIEF | 15 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 01944762 |
| CALMYLIN | 12.5 MG / 5 ML | SYRUP | TEVA CANADA LIMITED | MARKETED | DIN 00535230 |
| CALMYLIN ACE | 10 MG / 5 ML | SYRUP | TEVA CANADA LIMITED | MARKETED | DIN 02198630 |
| CALMYLIN PSE WITH CODEINE | 3.3 MG / 5 ML | SYRUP | TEVA CANADA LIMITED | MARKETED | DIN 02172917 |
| COUGH & CHEST CONGESTION | 20 MG / 20 ML | SYRUP | JUNO OTC INC | MARKETED | DIN 02539195 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.